1. Introduction {#s0005}
===============

MRI-guided radiotherapy planning (MRgRT) has attractive advantages over CT for its potential to deliver more personalized treatment. First, MRI has superior visualization of soft tissue anatomy for more accurate definition of target volumes and organs at risk (OARs). Second, emerging novel devices such as MR-Linear accelerators (MRL) create an opportunity to use MRI rather than CT as a tool for online target and OAR visualization and for adaptive re-planning during treatment course [@b0005]. Third, functional MRI sequences may leverage tissue-specific contrast agents, as well as uncover biomarkers that may predict treatment outcomes [@b0010], [@b0015].

MRgRT has been established in many cancer subsites, including brain, spine, liver and pancreas, prostate, and nasopharyngeal cancers [@b0010], [@b0015]. This landscape is expanding. For example, an MRgRT system (ViewRay, 0.35 Tesla, OH, USA) [@b0020] was operational in 2014 at the Washington University in St. Louis, and in the intervening four-and-a-half years has changed their practice for abdominal and breast cancers [@b0005], [@b0025]. There is reason to hope that these developments herald new indications for MRI, especially as improved systems with more precise targeting and steeper gradient drop-offs are grandfathered into practice. At our institution, we successfully treated the first patient in the United States using a recently FDA-approved high-field Elekta-Philips Unity MRL (Elekta AB, 1.5 T, Stockholm, Sweden; Philips, Amsterdam, Netherlands) [@b0030], [@b0035].

However, the integration of MRI with radiotherapy planning on a broader landscape faces many challenges including those related to MRI acquisition, geometric distortion, and onerous MR-CT registration techniques [@b0010], [@b0040], [@b0045]. At our institution, we already established that an MRI acquisition technique for simulation (i.e. in the treatment position) using RT planning immobilization devices improved performance over diagnostic (i.e. non-immobilized) MR acquisition for radiotherapy planning. This method demonstrated superior image quality, decreased geometric distortion, and better MR-CT co-registration [@b0050], [@b0055]. Prior work to ours has also confirmed the feasibility of MR acquisition in the treatment position [@b0060]. Nevertheless, we still lack a rigorous quantification of the quality of deformable and rigid MR-CT co-registration techniques and their anatomic fidelity when both MR and CT are acquired *in the treatment position*. MR-CT co-registration is potentially useful since MRI does not provide tissue electron-density information needed to calculate radiation dose. Prior studies suggest that deformable image registration (DIR) techniques may offer an advantage over conventional rigid image registration (RIR) for head and neck cancer (HNC) patients [@b0065], [@b0070], [@b0075], [@b0080], [@b0085]. Nevertheless, not all these studies evaluated the quality of DIR across a robust number of anatomic regions of interest (ROIs), and some used MRIs acquired using standard diagnostic acquisition techniques. To this end, we assessed the quality of MR-CT co-registration using commercially available image registration software for images acquired using strict RT immobilization techniques for both MRIs and CTs in HNC cancer patients receiving definitive IMRT. The specific aims are: 1) Assess whether the use of DIR software provides an advantage over the conventional RIR, and 2) Determine the quality of MR-CT registration tools for HNC using overlap and surface distance metrics.

2. Methods {#s0010}
==========

2.1. Study population {#s0015}
---------------------

Eligible patients for this study had biopsy-proven intact squamous cell carcinoma of the head and neck, treatment with curative-intent intensity-modulated radiation therapy, no chemotherapy between CT and MRI scans, and not greater than 4 weeks between CT and MRI acquisition to avoid conflating our results with anatomic changes attributable to disease progression or treatment. For patients that met the criteria, nonenhanced simulation CT and nonenhanced simulation T2-weighted (T2w) MRI Digital Imaging and Communications in Medicine (DICOM) scans were prospectively acquired from the University of Texas MD Anderson Cancer Center clinical databases in agreement with an IRB protocol designed to evaluate imaging parameters for MR simulation. Anonymized scans are made available online at <https://figshare.com/s/a5e09113f5c07b3047df>.

2.2. Immobilization technique {#s0020}
-----------------------------

For both CT and MRI, patients were immobilized in the treatment position using a customized head, neck, and shoulder thermoplastic masks, mold head support, and dental stent. For further details we refer the reader to the MRI immobilization protocol we have previously validated [@b0055].

2.3. Imaging properties {#s0025}
-----------------------

Non-contrast enhanced simulation CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 and 434 mA at 120 kVp. All scans had slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections were displayed in 512 × 512 pixel matrices and reconstructed in diameters between 500 and 600 mm. Non-contrast enhanced simulation T2w MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 and 101.82 ms. All scans were acquired with slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections were displayed in 512 × 512 pixel matrices and reconstructed in 256 mm diameters. The median time between CT and MRI acquisition was 8 days (range 1--16 days).

2.4. Manual segmentation of ROIs {#s0030}
--------------------------------

Anatomic ROIs included the C1-C4 vertebrae, mandible, spinal cord, thyroid cartilage, genioglossus, geniohyoid, hyoglossus, soft palate, tongue, and bilateral mastoids, submandibular and parotid glands, anterior digastrics, myelohyoids, masseters, medial and lateral pterygoids, sternocleidomastoids, internal jugular veins and common carotid arteries. These were contoured on CT and T2-MRI images independently by four radiation oncologists (M.A.M, M.K.J., S.P.N., H.E.) with at least five years of experience in head and neck radiotherapy (including residency) and approved by the principal investigator (C.D.F). All CT and MRI scans were acquired between 11/21/2013 and 06/09/2016. Each patient's CT and MRI pair was contoured by the same radiation oncologist to evade interobserver variability per patient.

2.5. Image registration {#s0035}
-----------------------

Three DIR algorithms (Admire version 1.13.5, a commercial research tool, Elekta, Stockholm, Sweden; Pinnacle v. 9.1, Philips Radiation Oncology Systems, Madison, WI, USA; and Velocity-deformable, Velocity AI, version 3.0.1, Atlanta, GA, USA) and one RIR algorithm (Velocity-rigid, Velocity AI, version 3.0.1, Atlanta, GA, USA) were used in this study. RT planning CT scan for each patient was used as the primary (i.e. fixed) image set and the T2-MRI was the secondary (i.e. mobile) image. Following the co-registration, we evaluated overlap and surface distance metrics for the 35 ROIs in all patients. [Fig. 1](#f0005){ref-type="fig"} summarizes the study workflow.Fig. 1Illustration of study workflow. T2-weighted MRI and non-contrast simulation CT scans were both acquired in the standard RT position and thirty-five ROIs were contoured on each scan by an expert radiation oncologist. MRI was then registered to CT by one of three DIR algorithms or by RIR, and performance metrics were calculated for the alignment of MRI contours and CT contours.

2.6. Statistical analysis and visualization {#s0040}
-------------------------------------------

Statistical analyses were performed in JMP Pro version 14.0 software (SAS institute, Cary, NC). Three performance metrics were calculated on 525 ROIs (1575 total measurements): Dice similarity coefficient (DSC) [@b0090], Hausdorff maximum distance (HD max), and Hausdorff mean distance (HD mean) [@b0095]. The DSC is calculated as two times the overlap volume (or area) between two contour volumes (or areas) A and B divided by the sum A and B. DSC values range from 0 to 1 where 0 indicates no overlap and 1 indicates perfect overlap ([Fig. 2](#f0010){ref-type="fig"}). Hausdorff distances are calculated in the following way: the distances between every point on contour A and its nearest point on contour B, and between every point on B and its nearest point on A, are noted. The HD max and mean are respectively the maximum and mean of these distances. Smaller HD max and mean values signify more similar contours. The results were assessed visually in histograms and were tested with Shapiro-Wilks [@b0100] to determine that the null hypotheses (that the distribution is normal) were in every case rejected (p values \<0.0001). Therefore, nonparametric statistical tests were employed since they make no assumptions about the normality of their underlying distributions. Median metrics for each DIR algorithm were pitted against DIR for all ROIs using the Steel method with control (n = 105 tests) [@b0105]. On a per-metric basis, DIR algorithms were compared to RIR for all ROIs in aggregate (n = 3 tests). Data were aggregated by tissue type (muscle, bone, vessel, spinal cord, and gland), and median metrics per tissue type were evaluated against one another using the Wilcoxon method for pairwise comparisons (n = 12 tests) [@b0110]. The alpha threshold was lowered by a Bonferroni correction to account for multiple comparisons [@b0115]. Results were represented graphically in the Python programming language version 3.6.7 (Python Software Foundation, <https://www.python.org>) leveraging code housed in the Pandas version 0.23.4 [@b0120], Matplotlib version 3.0.1 [@b0125] and Seaborn version 0.9.0 (Michael Waskom, <http://seaborn.pydata.org/>) libraries.Fig. 2Illustration of metrics. The DSC is computed as $\text{DSC} = \frac{2\left( {\text{A} \cap \text{B}} \right)}{\text{A} + \text{B}}$ and may take values from 0 to 1. A larger number indicates better volume overlap. Hausdorff Distances are the minimum distances from every point in A to any point in B (e.g. red lines) and from B to A (e.g. blue lines). The maximum and mean of these distances are the HD max and HD mean. Smaller numbers indicate less extreme deviations between contour surfaces. HD max is more sensitive to projection-like deviations than DSC. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

2.7. Interobserver variability {#s0045}
------------------------------

To exclude the influence of interobserver variability, we statistically analyzed our results after stratifying by radiation oncologist. DIR algorithms were compared to RIR with the Steel Method using the DSC, HD max, and HD mean metrics on a per-radiation oncologist, per-tissue type basis (n = 162 comparisons) with an exception: the "cord" tissue type results (which consists of only one ROI, the spinal cord) could not be subjected to this test for two radiation oncologists because these two radiation oncologists each contoured the scans of only one patient.

3. Results {#s0050}
==========

3.1. Patient characteristics {#s0055}
----------------------------

Fifteen patients were identified who met study inclusion criteria. The median patient age was 57 years (range 45--81) and 80% were males. Primary tumor sites included the tongue base and tonsils ranging from T1--T4, and 87% had nodal involvement. In all but one patient the tumor was found to be HPV positive. Fifty-three percent of patients were treated with photon-based radiotherapy modalities, and 47% of patients were treated with protons. The median final dose was 70 Gy (range 67.75--70 Gy) and all treatments were delivered in 33 fractions. Additionally, 93% of patients underwent concurrent chemotherapy with either cisplatin or cetuximab, although chemotherapeutic treatment during the interval between CT and MRI was an exclusion criterion. Patient characteristics are summarized in [Table 1](#t0005){ref-type="table"}.Table 1Summary of patient characteristics.Median age57 (range 45--81)GenderMale12Female3EthnicityWhite12Hispanic2Black1Tumor siteBase of tongue7Glossopharyngeal sulcus2Tonsil6Tumor stageT12T28T33T42Nodal stageN02N11N212Median dose70 Gy (range 67.75--70)Number of fractions33Treatment modalityIMRT7VMAT1IMPT7Concurrent chemoCetuximab5Cisplatin9None1

3.2. Comparison of DIR with RIR {#s0060}
-------------------------------

Our results could not demonstrate a statistically significant improvement in any deformable algorithm's performance over a rigid registration alone, regardless of ROI assessed or metric used to make the assessment ([Fig. 3](#f0015){ref-type="fig"}). Likewise, no improvement could be demonstrated between DIRs and RIR when all ROIs were grouped in one aggregate (p values all \>0.05).Fig. 3Nonparametric Steel tests with control failed to demonstrate superiority of DIR to RIR. Steel tests were calculated comparing each DIR algorithm to RIR by individual ROI and performance metric. Resulting p-values are plotted on a heat map. No statistically significant difference exists between DIR and RIR for any ROI.

3.3. Registration performance by tissue type {#s0065}
--------------------------------------------

Soft tissue ROIs consistently demonstrated superior concordance across all registration methods, including RIR. Selected statistically significant differences are shown in [Fig. 4](#f0020){ref-type="fig"}. Median DSC and HD metrics are enumerated for all tissue types in [Table 2](#t0010){ref-type="table"}. The apparent trend is that muscle gland ROIs were superior to vessel and bone. For example, the median DSC was higher for muscle than for bone (0.66 vs 0.61, p value \<0.0001), and the median Hausdorff max and mean were lower (respectively 10.23 vs. 12.18, p value \<0.005; 0.94 vs. 1.29, p value \<0.0001), indicating superior performance in muscle than bone. This statistically significant pattern was also observed between gland and bone. Vessel ROIs (internal jugular veins and common carotid arteries) suffered the least conformal registration independent of DIR or RIR method, as well as the most volatile surface distance metrics.Fig. 4Nonparametric pairwise comparisons using the Wilcoxon method demonstrated improved registration fidelity for soft tissues compared to other tissue types. Selected statistically significant relationships are shown illustrating superior DSC, Hausdorff max, and Hausdorff mean results for muscle and gland ROIs compared to bone, vessel, and spinal cord ROIs. This trend is generally consistent for all registration methods. Vessel ROIs were the least conformal and exhibited the greatest variance in surface distance metrics.Table 2Median DSC and HD metrics per tissue type, stratified by registration algorithm and in aggregate.MedianBoneCordGlandMuscleVesselDSCDIR 10.610.670.750.680.50DIR 20.600.590.740.640.43DIR 30.600.670.750.780.60RIR0.580.630.740.650.50In aggregate0.610.650.750.660.47  HD max (mm)DIR 112.526.3710.4210.0415.9DIR 211.786.1010.0510.1215.86DIR 312.687.7510.3810.9715.78RIR12.248.3910.7410.0815.53In aggregate12.187.5610.4210.2315.77  HD mean (mm)DIR 11.270.710.590.882.06DIR 21.230.930.601.032.16DIR 31.260.740.550.932.05RIR1.390.960.630.941.93In aggregate1.290.840.600.942.05

3.4. Comparison between radiation oncologists {#s0070}
---------------------------------------------

In all comparisons of results between radiation oncologists there was no statistically significant difference between any DIR algorithm and RIR, with one exception for one radiation oncologist in one tissue type (+0.07 median DSC conformality for the muscle tissue type with Admire DIR over RIR, p = 0.027 after Bonferroni correction). This single result notwithstanding, these results demonstrate that our data are not confounded by interobserver variability.

4. Discussion {#s0075}
=============

This study did not demonstrate that commercially-available DIR algorithms confer a better registration than RIR alone for simulation T2-weighted MRI registration to simulation CT in the context of HNC radiotherapy workflow. Since our primary objective of this study was to evaluate the quality of registration methods for MRI applications in radiotherapy planning, treatment, and post-treatment surveillance, this result is informative. We used rigorous, nonparametric statistical methods to compare between DIR and RIR, but the statistical rigor may be moot because none of the registration algorithms -- deformable or rigid -- achieved robust, clinically satisfactory fidelity to manually segmented anatomy. Across all ROIs, the median DSCs were only 0.65, 0.62, 0.63, and 0.63 for Admire, Pinnacle, Velocity-deformable, and Velocity-rigid registrations, respectively. Notably, our conclusions do not nominally accord with Fortunati et al, who report improvement in DIR compared to RIR for MR-CT registration (acquired with patient-specific RT immobilization methods) over 12 segmented ROIs in 12 patients [@b0065]. However, per ROI, Fortunati et al. report differences in DSC and HD measurements between DIR and RIR that were practically indistinguishable even when statistically distinguishable (refer to [Fig. 3](#f0015){ref-type="fig"} in their paper). The left and right eye lens ROIs are exceptions, which do show meaningful improvements with DIR of approximately +0.2 DSC, −0.5 mm modified Hausdorff surface distance, and −2 mm 3-dimensional Hausdorff surface distance, but this may be explained by that fact that the eyes are not immobilized, as the authors discuss. Therefore, while statistically and nominally different, we believe that Fortunati et al.'s results concord with ours.

Ancillary to the discussion above, we did find that all registrations methods demonstrated superior concordance in soft tissue ROIs, consistent with the detailed soft tissue visualization intrinsic to MRI. Vessel ROIs were, as a group, the least concordant tissue type. This may be due to the difficulty of distinguishing vessels from surrounding tissue without the aid of contrast. Vessels are small and serpentine and can be difficult to delineate even for experienced clinicians. This suggests that for T2-weighted MRI to non-contrast CT registration, vessels may be the most difficult anatomic structures to faithfully represent for DIR or RIR. These findings suggest that registration algorithms may need the greatest improvement in head and neck anatomic regions that are not well visualized in MRI or may benefit from contrast.

In contrast to CT to CT co-registration where several studies showed the superiority of DIR over RIR in the context of diagnostic and simulation CTs co-registration [@b0130], [@b0135], [@b0140], [@b0145], our CT to MR co-registration results did not demonstrate the same trend of DIR superiority. The significant improvement in DIR for diagnostic CT to simulation CT is mainly attributable to the poor performance of RIR since the diagnostic CTs are not acquired under any structured positioning. For example, a previous study done by our group for CT-CT co-registration quality assurance showed markedly inferior RIR performance compared to the present study, in which both the CT and MRI were acquired according to RT immobilization protocols. Judged by DSC and HD metrics, MRI-CT RIR performance is nearly as good as the best CT-CT DIR for muscle and gland tissue types in that study, but not for other tissue types, particularly bone. In sum, DIR currently appears capable of achieving better overall concordance for diagnostic CT to simulation CT co-registrations than simulation CT to MRI co-registrations.

To further the integration of MRI in radiotherapy applications, our results allow for following one of three paths: 1) manage MRI-CT registration using rigid methods alone, or 2) improve the performance of existing DIR algorithms, or 3) approach MR-guided radiotherapy from MR-only workflows, relying on synthetic CT (sCT) generation and eliminating MR-CT registration altogether. The first path may be unattractive because of the mediocre performance of RIR already discussed. The second path may be a preferable alternative to the first, but currently the lack of an immediately viable DIR stalls the integration of MRI. Moreover, there is no guarantee when nor if an improved DIR algorithm will become available. Therefore, MR-only workflow using sCT may be the best path continuing MRI integration with radiotherapy applications.

Significant challenges to MR-only radiotherapy exist. Principally, the best metrics and parameters for quality assessment of sCT have not yet been established nor standardized, nor have the optimal methods for generating sCTs been established in large clinical trials [@b0040]. Multiple methods have been developed for generating sCTs, most of which fall into three groups: 1) voxel-based, 2) atlas-based, or 3) bulk-override [@b0040], [@b0045]. The plurality of methods are voxel-based and generate sCTs that model dose deposition with no more than 2.5% error from standard CT. Synthetic CTs have mean absolute errors (MAE) reported between 40 and 200 Hounsfield Units (HU), depending on body organ [@b0045]. Atlas-based methods have reported similar efficacies, but can be more computationally intensive and are challenged by atypical anatomy [@b0040]. Atlas-based sCT generation requires at least one image registration (sometimes more), but to an MRI atlas rather than to a CT. Although the acquisition and evaluation of sCTs lack standardization, the metrics in studies to date (ΔDose%, DSC, and HU MAE) seem to sustain the notion that clinically acceptable plans can be generated from standard MRI sequences, even though ultra-short echo time sequences improve the delineation of bone and air [@b0040], [@b0045]. At our institution a high field (1.5 Tesla) MRL treated the first patient in North America in January 2019, following suit behind University Medical Center Utrecht in the Netherlands, which pioneered the first treatment in late 2017 [@b0035].

In summary, we present results evaluating the performance of DIR and RIR algorithms for T2w simulation MRI to simulation CT registration. We found the median DSC to be mediocre even for tissue types that best lend themselves to registration, and that DIR conferred no improvement in registration fidelity over RIR when images were acquired with standard immobilization protocols. Together, these results either usher the timely improvement of existing co-registration methods or else herald the use of sCT over MRI-CT registration for MR-guided dose deposition modeling in HNC, thereby signaling the need for standardization of sCT acquisition methods and evaluation metrics in order to scale MR-guided radiotherapy applications.
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